News

Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenses

Euclid Vision Corporation (Euclid), a global leader in advanced orthokeratology (Ortho-K) lenses and proactive myopia management initiatives, is pleased to announce ABB Optical Group as a licensed manufacturer and distributor of the company’s Ortho-K lenses. ABB, known as the largest distributor of soft lenses in the United States, supplies nearly two-thirds of eye care professionals (ECPs) across the United States with optical products, services, and business solutions.

Given ABB’s reach, this new collaboration will provide greater access to Euclid’s clinically proven Ortho-K contact lenses to a much wider audience of ECPs. “The manufacturing and distribution arrangement capitalizes on the strengths of two leading companies in the specialty contact lens arena and manifests our shared vision of growing accessibility to myopia management products and services,” said Joseph Boorady, president and CEO, Euclid.

Euclid is the manufacturer of the Euclid Emerald® and Euclid MAX™ Ortho-K contact lenses, which are worn overnight and are designed to reshape the cornea, so patients wake up to clear vision. Euclid’s Ortho-K lenses have a unique design that yields an 87% first fit success¹ without requiring a trial set. ABB is well-equipped to support the manufacturing of Euclid’s lenses with their decades of gas permeable (GP) and custom soft lens manufacturing and specialty vision products distribution expertise.

“We are excited to work with Euclid and expand our licensed manufacturing, distribution, and myopia management product offerings with the addition of Euclid MAX lenses, a next generation Ortho-K product. Recognizing the continued rise of myopia as a serious eye-health issue, we are proud to bring an innovative Ortho-K design, which has the highest Dk of any US overnight Ortho-K brand, to our ABB customers.” said Aaron See, senior vice president of manufacturer partnerships, ABB.

Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050.² “Increased accessibility to Euclid’s Ortho-K lenses means ABB’s customers can broaden their myopia management initiatives and help more myopic children at a critical time in the myopia epidemic,” said Nitin Jain, chief commercialization officer, Euclid. “This trend presents both a clinical challenge and practice management opportunity for ECPs poised to best serve their myopic patients. Together with ABB, we can provide easier access to myopia management products to help mitigate the extent of this epidemic,” added Jain.

Visit the Euclid MAX landing page to get started.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation